Mortality Due to COVID-19 in the COVID-AGEBRU Study

Brugmann University Hospital160 enrolled

Overview

The COVID-Age Brugmann study aims to identify the clinical predictors of mortality risk in older patients admitted to an acute care unit due to COVID-19

The COVID-19 disease has been shown to be associated to higher mortality risk and health adverse consequences. Despite of the fact that the SAR-COV2 virus has been shown that affects every populations, the negative impact is higher in older people, pointing this population as the most severely affected. The COVID-Age Brugmann study aims to identify if comorbidity, geriatric syndromes, and health issues at admission are associated to mortality risk in older patients admitted to an acute care unit due to COVID-19

Study Type

OBSERVATIONAL

Enrollment

160

Conditions

Covid19 Old Age; Debility Morbidity, Multiple

Eligibility

Sex: ALLMin age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged 70 and older * Patients admitted to an acute care geriatric unit due to COVID-19 * Patients with COVID-19 by PCR, serology or CT scan suggestive of this disease Exclusion Criteria: * No other demographic or clinical exclusion criteria will be applied

Locations (1)

CHU Brugmann

Brussels, Belgium

Outcomes

Primary Outcomes

All-cause mortality during hospital admission (admission up to discharge time)

Vital status was obtained from medical records

Time frame: Through study completion, an average of one month.

Secondary Outcomes

Prevalence of medical diseases and geriatric syndromes

Clinical and demographical conditions, and geriatric syndromes

Time frame: Through study completion, an average of one month.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.